These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22142620)

  • 41. Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
    Wells MT; Eisenberg T
    Circulation; 2010 Dec; 122(23):e575; author reply e577. PubMed ID: 21135368
    [No Abstract]   [Full Text] [Related]  

  • 42. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
    Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734
    [No Abstract]   [Full Text] [Related]  

  • 43. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
    Ridker PM; MacFadyen JG; Wolfert RL; Koenig W
    Clin Chem; 2012 May; 58(5):877-86. PubMed ID: 22419750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
    Vos E; Rose CP; Biron P
    Circulation; 2010 Dec; 122(23):e576; author reply e577. PubMed ID: 21135369
    [No Abstract]   [Full Text] [Related]  

  • 45. The Jupiter trial--new territory for statins?
    Wheeler DC
    Nephrol Dial Transplant; 2009 Jul; 24(7):2036-7. PubMed ID: 19541666
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
    Nicholls SJ; Uno K; Kataoka Y
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1383-90. PubMed ID: 22059787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rosuvastatin in older patients with systolic heart failure.
    Kjekshus J; Apetrei E; Barrios V; Böhm M; Cleland JG; Cornel JH; Dunselman P; Fonseca C; Goudev A; Grande P; Gullestad L; Hjalmarson A; Hradec J; Jánosi A; Kamenský G; Komajda M; Korewicki J; Kuusi T; Mach F; Mareev V; McMurray JJ; Ranjith N; Schaufelberger M; Vanhaecke J; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
    N Engl J Med; 2007 Nov; 357(22):2248-61. PubMed ID: 17984166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP; Visseren FL; de Wit GA; Algra A
    BMJ; 2011 Mar; 342():d1672. PubMed ID: 21450800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
    Glynn RJ; Koenig W; Nordestgaard BG; Shepherd J; Ridker PM
    Ann Intern Med; 2010 Apr; 152(8):488-96, W174. PubMed ID: 20404379
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The editor's roundtable: JUPITER follow-up.
    Friedewald VE; Ballantyne CM; Davidson MH; Gotto AM; Ridker PM; Roberts WC
    Am J Cardiol; 2011 May; 107(10):1549-57. PubMed ID: 21539951
    [No Abstract]   [Full Text] [Related]  

  • 52. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].
    Olsson AG
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435
    [No Abstract]   [Full Text] [Related]  

  • 53. [Statins in primary prophylaxis of cardiovascular diseases].
    Kobalava ZhD; Villeval'de SV
    Ter Arkh; 2011; 83(9):70-5. PubMed ID: 22145392
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
    Ridker PM; Pradhan A; MacFadyen JG; Libby P; Glynn RJ
    Lancet; 2012 Aug; 380(9841):565-71. PubMed ID: 22883507
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rosuvastatin for cardiovascular prevention: too many uncertainties.
    Prescrire Int; 2009 Aug; 18(102):176. PubMed ID: 19746571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [From lipid target values to the JUPITER study. Significance of achieving lipid levels specified by the guidelines and deficiencies in practice].
    Márk L; Katona A
    Orv Hetil; 2009 Nov; 150(44):2012-8. PubMed ID: 19861287
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Vidt DG; Ridker PM; Monyak JT; Schreiber MJ; Cressman MD
    Clin Ther; 2011 Jun; 33(6):717-25. PubMed ID: 21704236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed.
    Perez A; Bartholomew JR
    Cleve Clin J Med; 2010 Mar; 77(3):191-4. PubMed ID: 20200169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice.
    Motsko SP; Russmann S; Ming EE; Singh VP; Vendiola RM; Jones JK
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1214-22. PubMed ID: 19780020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Most would fail to benefit from JUPITER Intervention.
    Plonk WM
    J Am Coll Cardiol; 2009 Aug; 54(8):744; author reply 744-5. PubMed ID: 19679258
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.